R&D

글로벌 신약 개발을 위한 동아ST의 도전은 계속됩니다.

License-in/Out

In & Out Licensing Partners
Highlights of Dong-A ST Partnerships
  • 2007
    Sivextro®
    Global L/O to Trius
    (merged to MSD)
  • 2008
    G-CSF
    L/O to GTS
    Japan
  • 2012-2015
    Suganon®
    L/O to Alkem, Geropharm,
    and Eurofarma
    India, Russia, Latin America,
    respectively
  • 2014
    Darbepoetin alfa
    biosimilar
    L/O to SKK
    Japan
  • 2016
    Immuno-oncology
    Global L/O to AbbVie
  • 2017
    Immuno-oncology Co-R&D
    agreement
    with AstraZeneca
  • 2018
    DA-9801
    Global L/O to NeuroBo
    DA-9803
    Acquired by NeuroBo
  • 2021
    DA-7310
    L/O to Yangte River China
    Ustekinumab biosimilar
    Global L/O to Intas
  • 2022
    DA-1241, DA-1726
    Global L/O to Neurobo
    NESP biosimilar
    L/O to Polifarma
Highlights of Dong-A ST Partnerships (Co R&D, In-Licensing)
  • 2009
    Flivas®
    (Naftopidil)
    L/I from Asahi Kasei, JP
    (launched: 2012)
  • 2014
    Teribone®
    (teriparatide)
    L/I from Asahi Kasei,
    JP (launched: 2016)
    L/O to GTS
    Japan
  • 2015
    Acelex®
    (polmacoxib)
    L/I from Crystal Genomics, KR
  • 2016
    Jublia®
    (efinaconazole)
    L/I from Kaken, JP
    (launched: 2017)
    Epigenetic oncology
    Co Research &
    L/I from Beactica, Sweden
  • 2017
    Edarbi®
    (azilsartan medoxomil)
    Co-promotion agreement
    w/ Takeda Korea
    Immuno-oncology
    Co-R&D agreement
    with AstraZeneca
  • 2018
    C-REV
    (oncolytic virus)
    L/I from Takara Bio, JP
  • 2020
    SHR-1701
    (PD-L1/TGF-bRII)
    Co Development
    with Hengrui, CN
  • 2021
    Actonel®
    (risedronic acid)
    L/I from Theramex, UK
    PROTAC
    Co R&D agreement
    with KRICT, KR
    Autoimmune disease
    Co R&D agreement with
    Genesen, KR